These findings were further supported by treatment of HEK-293, DAOY, and BCC cells with GANT61, a small molecule inhibitor that specifically targets the GLI1/2 DNA binding site, which resulted in decreased proliferation in all cells, but predominantly in DAOY and BCC cells expressing tGLI2 or FHL2-GLI2 (Fig. 5d). The gene discussed is GLI1; the disease is skin basal cell carcinoma.